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Strengths and limitations of this study
 ► The first study investigating referral to a commercial 
weight loss programme during smoking cessation.
 ► Computer generated randomisation with allocation 
concealment.
 ► Weight measured and abstinence verified by ex-
haled CO.
 ► Small study with poor recruitment but reverse power 
calculation showed greater than 80% power to de-
tect change in primary outcome of weight.
ABSTRACT
Introduction Most people who stop smoking gain weight. 
Dietary modification may seem an obvious solution, 
but food restriction may increase cigarette craving and 
smoking relapse.
Trial design An unblinded parallel randomised controlled 
trial.
Methods Participants were adult smokers with a body 
mass index greater or equal to 23 kg/m2. Setting was 
National Health Service commissioned Stop Smoking 
Services, interventions were referral to a commercial 
weight management programme, plus stop smoking 
support (treatment group), compared with stop smoking 
support alone (control group). Objective was to compare 
weight change between interventions in smoking 
abstainers and not abstinent rates in all. Primary outcome 
was change in weight (kg) at 12 weeks. Randomisation 
sequence was computer generated and concealed until 
allocation.
Results Seventy- six participants were recruited, 37 were 
randomised to the treatment group and 39 to the control 
group. Change in weight was analysed in long- term 
abstainers (13 treatment, 14 control) only because the 
aim was to prevent weight gain associated with smoking 
cessation. Abstinence was analysed on an intention- to- 
treat basis (37 treatment, 39 control). At 12 weeks weight 
gain was less in the treatment than the control group with 
an adjusted mean difference of −2.3 kg 95% CI (−4.4 
to -0.1). Craving scores were lower (Mood and Physical 
Symptoms Scale craving domain −1.6 (–2.7 to –0.5)) and 
quit rates were higher in the treatment than the control 
group (32% vs 21%), although the trial was not powered to 
superiority in cravings and quit rates. No adverse events or 
side effects were reported.
Conclusion In people who are obese and want to quit 
smoking, these data provide modest encouragement that 
providing weight management at the time of quitting 
may be helpful. Those who are not obese, but who are 
informed about potential weight gain during their quit 
attempt, were uninterested in a weight management 
programme.
Trial registration number ISRCTN65705512
InTRoduCTIon
Weight gain is a well- known consequence 
of smoking cessation.1 2 A meta- analysis of 
weight data, from randomised controlled 
trials (RCTs), at 1- year postquit date showed 
that in untreated quitters there is a mean 
increase of 4–5 kg. However, variation in 
weight change is large, with about 16% of 
quitters losing weight and 13% gaining more 
than 10 kg.3 Nonetheless with the majority 
of people gaining weight smokers may be 
deterred from attempting to quit and this 
weight gain may offset some advantages of 
giving up smoking. Smoking cessation- related 
weight gain partly explains the finding that 
the incidence of type 2 diabetes is increased 
by up to 73% in the years after cessation,4–6 
there is a 30% increased risk of hypertension,7 
and a deterioration in glycaemic control in 
those with diabetes8 who quit compared with 
those who continue to smoke. Despite these 
concerns weight gain in quitters does not 
negate the risk reduction of cardiovascular 
morbidity and mortality in those who success-
fully quit smoking.9 There is some evidence 
to suggest the benefit may be mitigated10 
but the number of incident cases in higher 
weight gain categories are too small to draw 
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conclusions. Nonetheless, many people find this weight 
gain unacceptable and the greatest danger is it may deter 
individuals from quitting.11 Yet, restricting food intake 
may limit successful quitting as hunger increases urges to 
smoke12 13 and people who gain most weight quit more 
successfully.14
An individually tailored plan to reduce energy intake 
and increase exercise, with regular monitoring and adap-
tation of individual goals, appears to be the most prom-
ising way to prevent cessation related weight gain with 
the least risk of impeding a quit attempt.15 Commercial 
weight management providers (CWMPs) offer this type 
of support and are an effective way for many to lose 
weight through referral from National Health Service 
(NHS) primary care.16 Therefore, referral to a CWMP on 
prescription from the NHS Stop Smoking Services may be 
an effective way to prevent smoking- related weight gain 
without a detrimental effect on quitting success.
This study compares referral to a CWMP as part of stop 
smoking support with stop smoking support alone on 
changes in body weight in quitting smokers.
MeThodS
design
This was a parallel group, individually RCT to compare 
standard stop smoking behavioural support with an 
intervention that, in addition to providing standard stop 
smoking support, included personalised weight manage-
ment support, provided by Slimming World.
This was an open label trial, as blinding patients and 
smoking cessation advisors to allocation to intervention 
or control was impossible. The primary outcome was 
objectively measured weight and therefore the scope 
for bias is limited. Stop smoking advisors, who weighed 
participants, did not provide the weight control support 
and were unlikely to have a vested interest in interpreting 
weight change favourably. Full details of the methods for 
this trial can be found in the protocol paper17 but are 
summarised below.
Setting
NHS commissioned Stop Smoking Services were first 
recruited from Bristol and North Somerset Primary Care 
Trusts. Stop Smoking Services were invited to take part 
by letter and a follow- up phone call 2 weeks later. Clinics 
were only eligible to participate if they had two new 
service users coming through their doors each week. Due 
to poor recruitment we invited more clinics (n=30) to 
take part in the study by widening our area further across 
the West Midlands and South- West England. Addition-
ally we extended the planned duration of recruitment 
from 10 to 17 months, which was as far as our budgetary 
restraints would allow.
All individuals attending the Stop Smoking Services 
were invited to take part in the trial at their first visit when 
they set their quit date. At the second visit those wanting 
to participate in the trial gave their consent and were 
randomised to the control or intervention group. Those 
randomised to the intervention were given a referral to 
Slimming World, a location and a start date as near to 
their quit date. Those who declined to take part were 
invited to provide a reason.
Baseline measures were taken after randomisation and 
included age, gender, socioeconomic status, ethnicity, 
religion, Fagerström Test for Nicotine Dependence 
(FTND)18 and all dimensions of EQ- 5D (EuroQol, 
Rotterdam, Netherlands) as a measure of health- related 
quality of life19 presented as index values.
Participants
Daily adult smokers with expired CO >10 ppm and a body 
mass index (BMI) greater or equal to 23 kg/m2 were 
included. Pregnant smokers, those with a BMI <23 kg/
m2, those currently losing weight, or where weight loss 
was contraindicated, were excluded.
Participants with an ideal BMI, as well as those who are 
overweight, were included in the trial. This is because 
help is needed not only for quitting smokers who are over-
weight, but also for those of a healthy weight to prevent 
the weight gain that is associated with smoking cessation. 
Without engaging in weight management strategies to 
counteract the physiological and behavioural responses 
to smoking cessation, 85% of people who quit smoking 
will gain weight, regardless of their starting BMI.20
Randomisation
A randomisation sequence was generated using computer 
software. Stratified randomisation by stop smoking advisor 
with blocking within each stratum was used to ensure 
balance. The blocks were randomly ordered blocks of 2, 
4 and 6. Participants were randomised 1:1 to usual care 
or Slimming World with usual care. Stop smoking advi-
sors were unaware of the randomisation sequence; they 
opened sealed, numbered, opaque envelopes in turn.
Interventions and comparisons
Trial treatment providers
Trained NHS stop smoking advisors provided participants 
with standard smoking cessation support in both arms 
of the trial. This was withdrawal oriented behavioural 
support focusing on key behavioural change techniques, 
and a prescription of nicotine replacement or varenicline 
to relieve withdrawal symptoms. Support was on a weekly 
basis beginning 2 weeks before and until 4 weeks after 
quit day. Weight control support was provided by trained 
weight management counsellors employed by Slimming 
World. Slimming World is a CWMP which follows the 
National Institute for Health and Care Excellence criteria 
for clinical practice. It is commissioned by the NHS to 
provide a weight loss service to patients. Slimming World 
was the CWMP of choice as it works with populations to 
prevent excessive weight gain rather than solely focusing 
on weight loss, this was pertinent to preventing cessation 
related weight gain.
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Intervention
In addition to usual care, participants attended Slimming 
World for 12 weeks receiving support to lose weight or 
prevent weight gain. Slimming World consultants typically 
agree weight management targets with their members at 
the first appointment and then work with their members 
to achieve this through regular weight monitoring, 
controlled amounts of high energy foods and personal 
eating plans.
Control
Participants were encouraged to quit smoking first, before 
tackling weight. Stop smoking advisors advised satiating 
hunger with healthy foods, which is standard care, but 
did not provide detailed or personalised advice regarding 
weight management.
outcome measures
Primary outcome measure
Change in measured weight from baseline to 12 weeks 
postquit day in abstinent smokers. Abstinence was 
prolonged abstinence, defined according to the Russell 
Standard.21
Secondary outcome measures
 ► Weight at 4 weeks postquit date.
 ► Weight at 6 months from baseline.
 ► Abstinence at 4, 12 and 26 weeks.
 ► Participant acceptability measured quantitatively by 
response, attrition rates and a decliner’s reasons for 
not participating.
 ► Feasibility of running the trial within the Stop Smoking 
Services was measured by an open text questionnaire 
asking for comment.
Exploratory outcomes measures
 ► Change in EQ- 5D index values.
 ► Cigarette withdrawal symptom scores as measured by 
the Mood and Physical Symptoms Scale (MPSS).22
 ► Associations of change in religious engagement 
(adapted from CSI- MEMO23) and religious coping 
(religious coping index24) as positive use of individu-
al’s spiritual reserve to change weight25 and smoking 
behaviour26 is increasingly evidenced.
Statistics and data analysis
Sample size
Difficulty in recruiting resulted in it being economically 
unaffordable to continue the trial; therefore, the decision 
was made to stop the trial early.
Following the full analysis of our outcome data we 
conducted reverse power calculations. This showed that 
we had >80% power, at an alpha error rate of 0.05, to 
detect the observed differences in weight change in our 
sample at 12 weeks between the treatment and control 
groups. Given a large observed difference in quit rates 
between the control and treatment groups we also had 
90% power at an alpha error rate of 0.05 to determine 
non- inferiority, using a non- inferiority limit of 19%.27
Our original sample size had been conservative 
assuming we would see 20% wt. gain in the treatment 
group, rather than the weight loss we actually saw. This 
would have required 32 quitters in each trial arm at 12 
weeks; instead, we achieved 8–10 quitters at that time 
point. To achieve 32 quitters in each trial arm, based on 
a conservative estimate that only 20% of those recruited 
would be quit at 12 weeks, we wanted to recruit 160 per 
trial arm. Instead, we only recruited 76 smokers in total, 
but the quit rates in the treatment group were higher 
than expected.
Analysis
The change in weight was analysed in long- term 
abstainers only because only long- term abstainers gain 
more weight over time than the general population and 
because the aim was to prevent weight gain on smoking 
cessation.20 Therefore, as this comparison was made in 
abstainers only, and not those randomised to control or 
treatment groups, investigation of baseline differences 
was conducted between these groups. To identify likely 
confounding variables selected baseline characteristics of 
age, weight, BMI, FTND, gender, ethnicity and pharma-
cotherapy were compared, between quitters at 4, 12 and 
26 weeks postquit in the control and treatment groups, 
using t- tests and χ2 statistics. Weight change in the inter-
vention and the control arm of the study was presented 
descriptively using means and SDs and the mean differ-
ence and 95% CIs between the two arms calculated using 
multiple linear regression with adjustment for baseline 
differences.
Abstinence was analysed on an intention- to- treat (ITT) 
basis, assuming all those not present at follow- up had 
relapsed.21 As we recruited fewer people than intended, 
we could not assume effective randomisation and so 
investigated whether there were any differences in base-
line characteristics between the control and treatment 
groups. Adjustment for these was then made using logistic 
multiple regression to obtain an ORs for becoming 
abstinent.
The quality of life (EQ- 5D) was presented as index values 
calculated from interim scoring for the EQ- 5D- 5L spread-
sheet for UK values,28 means and SD of the EQ- 5D Visual 
Analogue Scale (VAS) were also presented following the 
EQ- 5D- 5L reporting guide.
The change in exploratory measures were presented 
with descriptive statistics and analysed using multiple 
linear regression. We also reported descriptive data about 
the acceptability of the intervention, supplemented 
by comments from questionnaires completed by Stop 
Smoking Service practitioners. We analysed these using 
manifest content analysis of a broad surface structure 
reflecting what was literally said.29 Open comments were 
broken down into individual codes of meaning then built 
up into subthemes and themes which summarised the 
data.
All participants gave their written informed consent to 
participate in the study.
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Figure 1 Flow of participants through trial. ITT, Intention To Treat.
Patient and public involvement
A patient advisory group were asked to comment on the 
concept of the study and the perceived acceptability of 
the proposed intervention, feedback was positive and so 
study plans progressed.
Participant reimbursement for attending follow-up visits
Participants received £5 payment for travel and inconve-
nience at the 12- week and 26- week follow- up visits.
ReSulTS
Potential participants
Thirty different stop smoking clinics in the West Midlands 
and South- West of England inclusion criterion of treating 
at least two new service users attending a clinic each 
week. Potentially over 4400 participants could have been 
accessed over our 17- month recruitment period and 
invited to take part in the trial. Of those who declined 
to take part 128 individuals provided us with a reason. 
Eighty- three people agreed to take part and were screened 
for eligibility, seven were ineligible (four were already 
losing weight through attending a commercial weight 
loss provider) and 76 individuals were randomised. Of 
these, 37 were randomised to the treatment group and 
12 returned for the 26- week follow- up, while 39 were 
randomised to the control group of which 10 returned 
for the 26- week follow- up. The majority of those not 
responding to follow- up did so in the first 4 weeks of the 
trial and continued to ignore requests thereafter. Eight 
withdrew from the trial for various reasons, one indi-
vidual in the control group did so to join Slimming World 
and two individuals in the intervention group said it was 
too difficult to quit and diet at the same time, another 
reported returning to smoking (figure 1).
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Table 1 Characteristics of those who declined to take part 
and those who participated in the Slimming World in UK 
Stop Smoking Services trial
Characteristics Decliners (n=128)
Participants 
(n=76)
Age 45.3 (14.1) 46.7 (13.5)
  Ethnicity (%)
  White British 93% (n=119) 88% (n=67)
  White Irish 1% (n=1)
  White other 2% (n=3)
  Indian 2% (n=2) 1% (n=1)
  White and Asian 3% (n=2)
  Black—other 1% (n=1) 8% (n=6)
  Unknown 1% (n=2)
Gender (n=71)
  Female 55% (n=70) 65% (n=46)
  Male 45% (n=58) 35% (n=25)
BMI category (Self- report) 
(n=123)
(Measured) (n=73)
  Underweight 7% (n=8) 0% (n=0)
  Healthy weight 58% (n=71) 12% (n=9)
  Overweight 35% (n=43) 34% (n=25)
  Obese 1% (n=1) 53% (n=39)
BMI, body mass index.
Characteristics of ‘decliners’ and participants
Those who provided a reason for declining to take part 
(decliners) and those who agreed to participate were 
of a similar mean age and mostly white British people. 
Women were more likely than men to enrol in the trial, 
but the most striking difference related to baseline weight 
status. Practically everyone who was obese agreed to join 
the trial, while a minority in the other BMI groups did so 
(table 1).
Over half those who declined to take part did so because 
they were not interested in weight control. (Proportion-
ally more who gave this reason had a healthy weight rather 
than being overweight (data not shown).) Over 20% of 
reasons for declining were because people did not have 
time. Seventeen per cent said they were not prepared to 
go to Slimming World, similar numbers said they could 
not quit smoking and diet at the same time. Medical 
reasons and reasons related to the research process such 
as the principle of taking part or being randomised to the 
control were not commonly reported (online supplemen-
tary figure 1).
Baseline characteristics of participants in the treatment and 
control group at baseline
Baseline characteristics of participants were investigated 
between the control and treatment groups as failure to 
recruit to target sample size could have resulted in an 
imbalance. Those in the control group were significantly 
younger and with a higher BMI than the treatment group 
(table 2) and adjustment was made for this in the analysis 
of outcomes.
Weight change during abstinence
Among abstinent participants, there was a steady mean 
weight gain over time in the control group, whereas 
weight reduced at each time point in the treatment 
group. In those who were quit at 4- week follow- up there 
was an adjusted mean difference of −1.2 kg (−2.5 to 0.1) 
weight change between those in the intervention group 
and those in the control group. At 12 weeks the differ-
ence was greater −2.3 kg (–4.4 to –0.1) and some of this 
initial difference in weight loss between the trial arms was 
maintained at 26- week follow- up (−3.1 kg (−6.9 to 0.8)) 
(table 3). No confounding variables were identified in the 
quitters between treatment and control groups at week 4 
and 12 postquit (results no shown), age was a potential 
confounding variable for those who remained quit at 26 
weeks and adjustment for age was included in the analysis 
of difference in weight between the trial arms.
Change in abstinence (intention-to-treat analysis)
In the control group 13 of 39 participants (34%) were 
abstinent at 4 weeks and in the treatment group 14 of 
37 (38%) were abstinent. By 12 weeks 8 (21%) partici-
pants in the control and 12 (32%) in the treatment group 
remained abstinent. At 26- week follow- up five (13%) 
participants in the control group remained abstinent and 
eight (22%) in the treatment group.
Change in exploratory outcomes
Change in the MPSS craving domain (MPSS- C) at all 
time- points showed a greater reduction in the treatment 
than the control group, with mean adjusted differences 
ranging from 0.7 to 1.9 on a scale of 0–10. In the mood 
domain, MPSS- M, in the longer term (26- week follow- up) 
there was a greater reduction in negative affect in the 
treatment group than the control group but the adjusted 
mean difference was negligible −1.3 (−3.7 to 1.2) on a 
scale between 7 and 35. The effect on hunger and MPSS- P 
within and between the trials arms was negligible at all 
time- points. There was negligible change in religious 
coping and the index values of EQ- 5D between the trial 
arms. The VAS for quality of life improved between 4% 
and 6% in both groups across all time points (table 4).
Practitioners’ comments on trial delivery
Three main themes came out of the content analysis of 
practitioners’ comments, these were ‘Aspects related to 
research processes’, which included positive aspects such 
as ease of implementation, however, additional time and 
paperwork particular on the part of the practitioner, 
and also the perceived burden for the participant, were 
viewed negatively.
Randomisation to the control group disappointed 
both the participant and the practitioner; practitioners 
reported viewing Slimming World vouchers as an incen-
tive and this suggested misunderstanding of the nature 
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Table 2 Baseline characteristics by randomisation
Characteristic (mean 
(SD)/% frequency)
Control 
(n=39)
Treatment 
(n=37)
Age (years) 50 (15)* 44 (12)*
BMI (kg/m2) 31.6 (6.3)* 29.3 (4.3)*
FTND (scores range: 1–10) 5.7 (2.2) 5.8 (2.1)
MPSS- M (scores range: 
7–35)
12.7 (5.7) 12.8 (4.1)
MPSS- C (scores range: 
0–10)
6.9 (1.7) 7.3 (1.1)
MPSS- P (scores range: 
3–15)
4.2 (1.8) 3.9 (1.1)
MPSS- T (scores range: 
10–60)
23.8 (7.3) 24.1 (4.9)
EQ- 5D
  Index value 0.759 (0.268) 0.848 (0.105)
  VAS (100- point scale) 61 (23) 67 (15)
Using religion to cope score 
(scores range: 1–10)
(n=23) (n=21)
2.7 (2.6) 3.7 (2.9)
Gender (n=38) (n=33)
  Male 29% 44%
  Female 71% 56%
Ethnicity
  White British 92% 84%
  Indian 3%
  Unknown 3% 13%
Highest qualification (n=38) (n=32)
  No formal qualification 18% 25%
  GCSEs/O levels 21% 28%
  A levels 42% 31%
  Degree 13% 9%
  Higher degree 6% 7%
Employment (n=38) (n=32)
  Employed 55% 63%
  Long- term sick 11% 0%
  Looking after others 3% 6%
  Retired 21% 13%
  Unemployed 8% 13%
  Other 2% 5%
Religious (n=37) (n=30)
  No 95% 87%
  Yes 5% 13%
Supportiveness of religious 
community
(n=20) (n=14)
  A lot 5% 35%
  A little 15% 25%
  Not at all 80% 30%
Impact of religious belief (n=11) (n=10)
Continued
Characteristic (mean 
(SD)/% frequency)
Control 
(n=39)
Treatment 
(n=37)
  Comfort 91% 100%
  Stress 9% 0%
Pharmacotherapy used (n=16) (n=15)
  Nicotine replacement 
therapy
38% 40%
  Varenicline 62% 60%
Family history of diabetes (n=36) (n=31)
  Yes 25% 26%
  No 75% 74%
Impaired glucose tolerance
  Yes 16% 19%
  No 84% 81%
Absolute diabetes 
prevalence
(n=32) (n=32)
  Yes 14% 13%
  No 86% 87%
*P<0.1 between control and treatment groups.
A level, advanced level exams; BMI, body mass index; FTND, 
Fagerström Test for Nicotine Dependence; GCSE, General 
Certificate of Secondary Education; O level, ordinary level exams; 
MPSS- C, Mood and Physical Symptoms Scale craving domain; 
MPSS- M, Mood and Physical Symptoms Scale mood domain; 
VAS, Visual Analogue Scale.
Table 2 Continued
Table 3 Change in weight in quitters at 4, 12 and 26 weeks 
postquit
Change 
in weight 
(kg) from 
baseline in 
quitters at Control Treatment
Difference in weight 
change (treatment–
control) mean (95% CI) 
adjusted for baseline 
weight as covariate
4 weeks 
postquit
(n=13) (n=14)
0.7 (1.5) −0.7 (1.8) −1.2 (−2.5 to 0.1)
12 weeks 
postquit
(n=8) (n=12)
2.0 (1.9) −1.3 (3.3) −2.3 (−4.4 to −0.1)
26 weeks 
postquit
(n=5) (n=8)
2.3 (2.2) −0.9 (2.5) −3.1 (−6.9 to 0.8)*
*Also adjusted for age (p<0.1 between treatment and control in 26- 
week quitters).
and value of randomisation and the need to promote 
the control arm as a good alternative. Such attitudes may 
have fuelled disappointment and subsequent drop out. 
The second theme was ‘An opportunity to address weight 
issues’, this opportunity was predominantly seen as a posi-
tive aspect of the trial and practitioners anticipated this 
would generate great interest from participants. However, 
practitioners were somewhat surprised that participants 
did not seem to want to address weight, there was mention 
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that fewer people at the time of this trial were seeking 
Stop Smoking Services than expected, and high rates of 
drop out were also problematic. These comments led 
to the third theme ‘Poor participant interest and atten-
dance’ which characterised experience of delivering the 
trial (online supplementary table 1).
dISCuSSIon
Summary of results and consistency with other findings
The aim of the study was to prevent cessation related 
weight gain—which as discussed in the introduction 
has both clinical and psychological consequences, the 
most harmful of which may be considered as relapse to 
smoking. The trajectory of cessation related weight gain 
was seen by a consistent weight increase in the control 
group. In comparison, the treatment group lost weight at 
each of these time points. Referral to the 12- week Slim-
ming World programme plus usual stop smoking support 
achieved significantly less weight gain than usual stop 
smoking support alone. This adjusted difference (−2.3 kg 
(–4.4 to –0.1)) was apparent at 12 weeks postquit and is 
slightly greater than that seen in other trials comparing 
personalised weight management to usual care (−1.1 kg 
(–1.9 to –0.3)).14 This was partially sustained at 26 weeks 
postquit (−3.2 kg (−6.9 to 0.8)).
However, we were unable to recruit to our target sample 
size and these results lack precision.
Percentage quit was no worse in the treatment than 
the control group; it was slightly higher in the treatment 
group but the trial was underpowered to test superiority. 
MPSS craving scores dropped further in the treatment 
than the control group (>1- point difference on 10 point 
scale at 12 and 26 weeks). Hunger ratings were similar in 
both groups across all time points.
Comparing our findings with the meta- analyses of 
personalised weight management versus no weight 
management at 26 weeks,15 our study achieved a similar 
quit rate in our treatment group (22%) as in the control 
groups of other studies (21%). However, the quit rates in 
our control group was lower than in these other studies 
(13% vs 19%) which may account for the difference in 
quit rates we saw here.
Taken together these results suggest that referral to 
a commercial weight loss provider, such as Slimming 
World, at the time of a quit attempt can prevent cessation- 
related weight gain without negatively impacting a quit 
attempt. However, we cannot draw firm conclusions given 
our small sample size.
limitations
The greatest limitation to this study was the difficulty in 
recruiting which led to the small sample size. Anecdotally 
stop smoking advisors often cite weight gain is raised as a 
concern in clinics and were anticipating a high uptake for 
this trial, however, we found that when given the opportu-
nity participation was poor and more than 50% of people 
who gave a reason for declining reported it was because 
they were ‘uninterested in weight control’.
While we do not know the reasons for everyone who 
declined, these results suggest that weight gain may 
not be as much as a barrier to quitting smoking as is 
commonly believed, particularly in those who are not 
obese. However, all those who were invited to participate 
in the trial had already decided to quit smoking and were 
looking for support in that goal. In addition, people who 
were already losing weight or attending a commercial 
weight loss programme were ineligible to take part (9% 
the 44 screened for eligibility). The Office for National 
Statistics reports weight gain only deters 5% of people 
from quitting and only 3% of people cite it as a reason 
for returning to smoking.30 In light of this, and in view 
of the evidence that the cardiovascular benefits of quit-
ting are evident despite weight gain,9 10 we can reassure 
quitters who are worried about gaining weight that they 
need not be unduly concerned. In fact, evidence from 
a randomised control trial in the USA (350 quitters at 6 
months) suggests that counselling quitters to reduce their 
weight concerns (through CBT telephone counselling 
compared with standard quit advice) leads to similar rates 
of quitting and a significant difference in weight change 
in favour of the counselling group (−0.5 kg vs 1.0 kg). 
Such counselling involved identifying and addressing 
maladaptive thoughts about body shape and weight, 
discouraged restrictive dieting, educated quitters on the 
relationship between weight gain and smoking cessation 
and encouraged an acceptance of moderate weight gain 
after quitting.31
The small sample size also means that we cannot assume 
effective randomisation, therefore we cannot account for 
any unmeasured of residual confounding which may have 
otherwise been explained the results we found.
The trial was also limited by a short- term follow- up at 
6 months postquit (3 months post- treatment interven-
tion), therefore the long- term consequences of the effect 
on weight gain prevention are unknown. However, meta- 
analysis data from RCTs suggests that 17% of weight lost 
is maintained 5 years after the end of moderate weight 
management interventions32 so we might expect a similar 
trajectory here. This intervention in Stop Smoking 
Services may therefore have limited impact in the long- 
term prevention of weight gain associated with smoking 
cessation. It is also important to note that the magnitude 
of weight change is relatively small (mean reduction 
1.1 kg at 12 weeks) only 1.3% wt. loss considering the 
mean weight of all participants at baseline was 86.9 kg.
Another limitation is the high rate of loss to follow- up 
in both the control and treatment arms of the study. The 
provision of free weight management advice did not deter 
attrition. High attrition is common in smoking cessa-
tion trials and is usually due to participants returning 
to smoking and as such the standard approach in anal-
ysis is to assume this.21 However, our trial showed higher 
loss to follow- up compared with other smoking cessation 
trials,33 this may have been due to staff time pressures 
copyright.
 o
n
 February 10, 2020 at Coventry University. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032271 on 26 January 2020. Downloaded from 
9Lycett D, et al. BMJ Open 2020;10:e032271. doi:10.1136/bmjopen-2019-032271
Open access
reported by practitioners which may have limited their 
continued attempts to make contact with those who did 
not attend.
Additionally, not all data were fully completed at base-
line, there were disproportionally more missing values 
in the treatment than the control arm but we have no 
reason why this might be the case.
Our trial did show that a few people were interested in 
preventing weight gain by attending a behavioural weight 
loss programme, and those who wanted to take part in 
the trial were more likely to be female and more likely 
to be obese. This is consistent with other findings that 
suggest women who are obese are likely to be the most 
weight concerned.34 Therefore, the generalisability of 
our findings are largely limited to these who are already 
overweight or obese.
For individuals who feel unable to make a quit 
attempt without concurrently controlling their weight, 
this trial suggests that referral to a behavioural weight 
loss programme may be a pragmatic option within stop 
smoking clinics.
Implications for future trials to prevent cessation related 
weight gain
 ► Stop smoking service practitioners consider a rela-
tively straightforward trial delivered with support to 
impose undue burdens on their time, limiting their 
willingness to approach potential participants. This is 
mostly due to the paperwork concerned with consent 
and follow- up. In low- intensity low- risk trials, we need 
to develop a method for achieving this that does not 
impose the same burdens as trials of much riskier 
interventions. In the meantime, trial lists need to 
understand this and make fewer demands by rede-
signing the trials.
 ► Most people who are stopping smoking are uninter-
ested in active behavioural support to prevent weight 
gain. However, where people already are overweight 
to the extent of being obese, most people were 
prepared to enter the trial and future trials may target 
this population.
 ► Practitioners and participants quickly become 
despondent if not randomised to their choice of inter-
vention, almost always the intervention group. More 
intensive training for practitioners in how to present 
trials to create equipoise is likely to be needed. There 
was a suggestion that quit rates were higher in the 
intervention than the control group and it may be 
helpful to explore qualitatively whether unhappiness 
at weight gain explains this.
ConCluSIon
Referral to the 12- week Slimming World programme 
plus usual stop smoking support achieved weight loss 
compared with weight gain seen with usual smoking 
cessation support alone throughout the quit attempt 
as far as 26 weeks. Quit rates, cravings for cigarettes, 
feelings of hunger and quit rates did not seem to be 
adversely affected although the recruited sample was 
too small to confirm this.
Recruitment into a trial of Stop Smoking Services 
referred into a behavioural weight loss programme 
was poor. They most common reason for declining to 
participate was no interest in controlling weight.
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